Background: Among diabetics, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality, and progression of their underlying disease. Finerenone is a novel, non-steroidal, selective mineralocorticoid-receptor antagonist which has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD), while revealing only a low risk of hyperkalemia. However, the effect of finerenone on renal and CV outcomes has not been investigated in long-term trials yet. Methods: The Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease (FIDELIO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important renal and CV outcomes in T2D patients with CKD. FIDELIO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 5.5 years. FIDELIO-DKD randomized 5,734 patients with an estimated glomerular filtration rate (eGFR) ≥25-< 75 mL/min/1.73 m 2 and albuminuria (urinary albumin-to-creatinine ratio ≥30-≤5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of primary outcome (overall two-sided significance level α = 0.05), the composite of time to first occurrence of kidney failure, a sustained decrease of eGFR ≥40% from baseline over at least 4 weeks, or renal death. Conclusion: FIDELIO-DKD will determine whether an FIDELIO-DKD Phase 3 investigators and site list are included in the online supplementary files
Background
Worldwide, over 2.5 million people receive renal replacement therapy, and this number is projected to grow and be more than double in 2030 [1] . Type 2 diabetes (T2D) is the most common cause of end-stage renal disease (ESRD) in the Western world, except for Taiwan, which has a higher prevalence of ESRD than the US [2] . Moreover, this trend in ESRD is rapidly increasing in Asia and Latin America [1] .
The current pharmacological strategy to reduce the rate of progression of kidney disease is the optimization of blood pressure control, lipid levels, and glycemic control, and has been in place since the 1990s [3] . Following the advent of the angiotensin-receptor blocker (ARB) trials almost 20 years ago [4, 5] , the sodium-glucose cotransporter-2 (SGLT2) inhibitor canagliflozin added to a renin -angiotensin system (RAS) blocker recently demonstrated a 34% relative risk reduction of the renal-specific composite endpoint of ESRD, a doubling of creatinine level, or death from renal causes [6] . For many years, T2D patients who have chronic kidney disease (CKD) and albuminuria > 300 mg/day have had guideline directives to use angiotensin-converting enzyme inhibitors (ACEIs) or ARBs [7, 8] . From mid-June 2019 onwards, SGLT2 inhibitors have been recommended in addition for patients with T2D with albuminuria > 300 mg/g if their estimated glomerular filtration rate (eGFR) is > 30 mL/min/1.73 m 2 , to reduce cardiovascular (CV) events, with increasing evidence that they may also slow kidney disease progression [9] .
While optimizing therapy with RAS blockers and SGLT2 inhibitors has markedly slowed CKD progression, it has not stopped it fully [6, 10] . Despite the use of ACEIs, ARBs, and the concomitant use of SGLT2 inhibitors, the rate of ESRD remains unacceptably high, with more than twice the normal decline in kidney function [6] . Mineralocorticoid receptor antagonists (MRAs) such as spironolactone demonstrate renoprotective effects in preclinical studies [11, 12] and are known to reduce albuminuria and blood pressure in patients with kidney disease, well-documented surrogates of CKD progression in men [13] [14] [15] . Thus, antagonism of mineralocorticoid receptor (MR) might be effective in slowing CKD progression in T2D [16] [17] [18] [19] .
Finerenone is a novel, non-steroidal, selective MRA that has much greater MR selectivity than spironolactone and better MR affinity than eplerenone in vitro [20] . Furthermore, unlike spironolactone and eplerenone, which reach higher concentrations in renal tissue in comparison to cardiac tissue [21] , finerenone is distributed relatively equally between the heart and the kidney, at least in rodents [22] . Lastly, its non-steroidal structure allows it to bind to the MR with high affinity and to inhibit recruitment of transcriptional co-activators involved in the expression of hypertrophic and pro-fibrotic genes more effectively than steroidal MRAs [23, 24] . This unique binding mode and lack of other hormonal stimulation compared to spironolactone mitigates against untoward effects like gynecomastia [25, 26] .
In a trial involving T2D patients with a clinical diagnosis of CKD (Mineralocorticoid-Receptor Antagonist Tolerability Study-Diabetic Nephropathy), finerenone compared to placebo showed only small mean changes in serum potassium and a low incidence of hyperkalemia leading to a low number of discontinuations with no evidence of a doseresponse relationship. Furthermore, finerenone compared to placebo demonstrated a statistically significant reduction in urinary albumin-to-creatinine ratio (UACR) at doses starting from 7.5 mg on top of standard of care (including an ACEI or ARB) after 90 days of treatment [27] .
These findings provided the rationale for initiating a large-scale Phase III program with finerenone investigating renal and CV outcomes in T2D patients with all stages of CKD in 2 large-scale outcome trials. In this study, we describe the design of the Finerenone in reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease trial (FIDELIO-DKD; ClinicalTrials.gov identifier: NCT02540993) and present the baseline characteristics of enrolled patients.
Patients and Methods

General Description
FIDELIO-DKD is an international, multicenter, randomized, double-blind, placebo-controlled, parallel-group, event-driven study, formally designed to assess whether finerenone reduces cardiorenal morbidity and mortality in T2D patients with CKD when used in addition to standard of care.
Study Population
The inclusion and exclusion criteria are summarized in Table  1 . Patients included in the trial are aged ≥18 years with T2D and a clinical diagnosis of CKD, pre-treated with ACEIs or ARBs for at least 4 weeks before the run-in visit, and had serum potassium ≤4. 8 Patients with a clinical diagnosis of CKD based on either of the following criteria at the run-in and screening visits: -Persistent high albuminuria defined as UACR ≥30 mg/g (≥3.4 mg/mmol) but <300 mg/g (<33.9 mg/mmol) and eGFR ≥25 but <60 mL/min/1.73 m 2 (CKD-EPI) and presence of diabetic retinopathy in the medical history or -Persistent very high albuminuria defined as UACR ≥300 mg/g (≥33.9 mg/mmol) and eGFR ≥25 but <75 mL/ min/1.73 m 2 (CKD-EPI)
Prior treatment with ACEIs and ARBs Close affiliation with the investigational site: for example, a close relative of the investigator or dependent person (e.g., employee or student of the investigational site)
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; DKD, diabetic kidney disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure; UACR, urine albumin-to-creatinine ratio; T2D, type 2 diabetes. DOI: 10.1159/000503713 have persistent high albuminuria (defined as UACR ≥30 but <300 mg/g), eGFR ≥25 but < 60 mL/min/1.73 m 2 , and presence of diabetic retinopathy in the medical history, or persistent very high albuminuria (defined as UACR ≥300 mg/g) and eGFR ≥25 but <75 mL/min/1.73 m 2 .
Two recruitment caps were pre-specified and closed per region. The first cap limited the randomization of patients with high albuminuria and diabetic retinopathy in the medical history to approximately 10% of all patients randomized. The second cap limited the randomization of patients with very high albuminuria and eGFR 60-75 mL/min/1.73 m 2 to 10% of all patients randomized with very high albuminuria at screening.
Study Design
The study design of FIDELIO-DKD is illustrated in Figure 1 . After signing the informed consent, a run-in visit was performed. If the patient met all inclusion criteria and none of the exclusion criteria, a mandatory run-in period that could last between a minimum of 4 and a maximum of 16 weeks started. At the end of the run-in period, a screening visit to confirm the patient's eligibility again took place, with subsequent randomization within 2 weeks.
To account for the high variability of UACR and eGFR, patients were permitted to switch either after the run-in or screening visit between FIDELIO-DKD and the second study of the program, Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD; ClinicalTrials.gov identifier: NCT02545049), before being randomized. As CKD in T2D is a disease continuum and variations in eGFR and UACR within the boundaries of this disease continuum do not affect the clinical risk, the switching of patients before randomization was deemed justified and necessary to reduce the burden on candidate study participants (run-in and screening assessments were not repeated after switching). A switchover from either trial was permitted only once.
Due to the anticipated recruitment period of > 2 years and the progressive nature of the underlying disease, re-screening was permitted once. Conditions for re-screening were amended in 2017 to shorten the re-screening period from 6 to 3 months and to allow re-screening even if the reason for the initial screen failure was an elevated blood potassium value (serum potassium > 4.8 mEq/L).
Eligible patients were randomized 1: 1 via an interactive telephone/web-based system to receive once-daily treatment with either finerenone or placebo. Treatment assignment was determined by computer-generated random sequence with stratification by region (North America, Latin America, Europe, Asia, Other), eGFR category at screening (25-< 45, 45-< 60, and ≥60 mL/min/1.73 m 2 ), and category of albuminuria at screening (high or very high).
The starting dose of study drug was selected based on eGFR measured at the screening visit: patients started on finerenone 10 mg/ day or matching placebo if their eGFR was 25-< 60 mL/min/1.73 m 2 ; if their eGFR was ≥60 mL/min/1.73 m 2 , the starting dose was 20 mg/ day. Up-titration of study drug to 20 mg/day is permitted at any time after Visit 2 (Month 1), down-titration to 10 mg/day at any time after start of treatment. Patients are instructed to take the study drug tablet orally, once daily at approximately the same time every day.
Central laboratory values, including serum potassium and serum creatinine, were obtained at all study visits and used for con- firmation of patients' eligibility, safety monitoring, renal endpoint reporting, and end-of-study statistical analysis. From Visit 1 onwards, blood potassium and serum creatinine are measured at all on-treatment visits at a local laboratory. The investigators are instructed to use these local values for dose titrations and safety monitoring. Patients' safety is monitored with physical examinations (including measurements of weight and vital signs) and 12-lead electrocardiograms at regular intervals throughout the study. Patients are assessed for adverse events and study endpoints at each visit and are requested to complete health-related quality-of-life questionnaires (EQ-5D-5L and Kidney Disease Quality of Life) at baseline and yearly thereafter.
The study protocol was approved by International Review Boards, independent Ethics Committees, and competent authorities according to national and international regulations. FIDELIO-DKD is conducted in accordance with the ICH Harmonised Tripartite Guideline for Good Clinical Practice. All study participants provided written informed consent before entering the study.
Objectives and Endpoints
The primary endpoint of FIDELIO-DKD is a composite of time to first occurrence of kidney failure, a sustained decrease of eGFR ≥40% from baseline over at least 4 weeks, or renal death. The component kidney failure is defined as either the occurrence of ESRD or eGFR < 15 mL/min/1.73 m 2 , confirmed by a second measurement at the earliest 4 weeks after the initial measurement. ESRD is defined as the initiation of chronic dialysis (hemo-or peritoneal dialysis) for at least 90 days or renal transplantation. The eGFR threshold of 15 mL/min/1.73 m 2 is consistent with the definition of kidney failure from Kidney Disease: Improving Global Outcomes [28] and was chosen to include an objective component to the endpoint because the decision to initiate dialysis therapy or kidney transplantation may be affected by factors other than eGFR.
The main pre-specified secondary endpoint is a composite of time to first occurrence of CV mortality and morbidity, as measured by the composite endpoint of time to first occurrence of CV death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for heart failure.
Other secondary endpoints include time to all-cause mortality, time to all-cause hospitalization, change in UACR from baseline to 4 months, and a composite endpoint of time to first occurrence of kidney failure or sustained decrease in eGFR ≥57% from baseline over at least 4 weeks or renal death.
Statistical Considerations Statistical Analyses
The primary efficacy endpoint for the statistical analysis is the time to first occurrence of the composite of onset of (i) kidney failure, (ii) a sustained decrease of eGFR ≥40% from baseline over at least 4 weeks, or (iii) renal death. Events included in the primary analysis will be counted from the day of randomization onwards until the planned end-of-study visit following the study sponsor's decision to terminate the study. Patients without a primary efficacy endpoint event will be censored at the date of their last contact with complete information on all components of the primary composite endpoint (up to and including the end-of-study visit). In case a non-renal death occurs within 5 months from the last visit (4 monthly visits plus maximum allowed time window of 30 days) and a subsequent clinic visit had been planned, the non-renal death date will be used as the censoring date.
To test for superiority of finerenone over placebo in prolonging the time to the first primary efficacy endpoint event, the null hypothesis of equal hazards in the 2 treatment groups will be evaluated via a log-rank test, stratified by the stratification factors region, eGFR category at screening, and category of albuminuria at screening. The treatment effect will be expressed as a hazard ratio with a corresponding confidence interval from a stratified Cox regression model. The statistical analyses will follow the intentionto-treat principle and will be based primarily on the full analysis set, consisting of all randomized patients considered valid for analysis. An analysis on the per protocol set, excluding patients with relevant deviations from the protocol, will be conducted as a sensitivity analysis in which only events occurring within 30 days after permanent treatment discontinuation will be considered.
To control the multiplicity arising from multiple tests, a weighted Bonferroni-Holm procedure will be used for the primary renal efficacy endpoint and the key secondary CV endpoint, followed by a hierarchical testing procedure of further secondary efficacy endpoints (as in the order given above). The weights assigned to the primary efficacy endpoint and the key secondary endpoint are given as 2/3 and 1/3, resulting in a minimal local two-sided alpha level of 3.3333 and 1.6667%, respectively, which will be increased to 5% for one test if the null hypothesis for the other test can be rejected. The full alpha level of 5% will be passed along hierarchically to the further secondary endpoints in a serial gatekeeping approach, that is, if and only if both the primary endpoint and the key secondary endpoint show significance. Within the hierarchy of the secondary endpoints, the full alpha is forwarded to the next null hypothesis as long as the previous null hypothesis is rejected, otherwise confirmatory testing stops at this point. As described under Powering and Sample Size, the actual significance levels used during the final analysis will be slightly adjusted based on the formal interim analysis. The testing strategy is further illustrated in Figure 2 . To declare the study successful, it will be considered sufficient to reject the null hypothesis related to the primary renal endpoint or key secondary CV endpoint.
Powering and Sample Size
As an event-driven study, FIDELIO-DKD has a power of 90% to detect a 20% relative risk reduction of finerenone versus placebo in the primary efficacy endpoint (equaling a hazard ratio of 0.8) based on a total of 1,068 patients with primary renal events and applying the log-rank test at a two-sided significance alpha level of 3.3333%. Further assumptions at the planning stage included an annual placebo event rate of 12% (assumed to be unaffected by treatment discontinuations), a common annual lost-to-follow-up rate of 0.7% in both treatment groups, an annual finerenone discontinuation rate of 5%, and a total treatment duration between 44 and 48 months, consisting of a recruitment period of 33 and 41 months with an equal recruitment pattern during the accrual period and a maximum treatment period of the last recruited patient of 11 and 7 months, respectively. Taking the ramp-up time during recruitment into consideration, this leads to an estimated required number of approximately 4,800 patients to be randomized. Assuming a screening failure rate of 50%, 9,600 patients need to be screened. To account for the lower-than-assumed event rates for the primary endpoint as observed during the conduct of the trial, the originally planned number of randomized patients was increased by approximately 1,000 patients.
One formal interim analysis is planned to be conducted when approximately 712 primary efficacy endpoint events (i.e., 2/3 of the DOI: 10.1159/000503713 finally intended number) have been observed. To guide the decision regarding early stopping of the study for success at the interim analysis, the Haybittle-Peto rule will be used, requiring a two-sided p value below 0.00270 for both the null hypotheses corresponding to the primary renal efficacy endpoint and the key secondary CV endpoint to be rejected and leading to a minimal alpha adjustment for the respective tests at the final analysis stage. Additionally, for lack of efficacy, a non-binding futility approach will be used to allow stopping the study at the interim analysis stage if the conditional power of rejecting the null hypothesis related to the primary endpoint at the final stage given the interim data falls to an unacceptably low level of 10% or less. 
Additional Statistical Considerations
Results
Recruitment of patients for FIDELIO-DKD began in
September 2015 and was completed in June 2018. A total of 13,911 individuals, including 604 patients who were rescreened, were enrolled at 1,062 sites in 47 countries, re-sulting in 5,734 randomized patients. During the run-in or screening phase but before randomization, 1,374 patients switched over from FIGARO-DKD. The rate of screening failure in all patients enrolled was 58.8 and 14.9% in patients who switched. Sixty patients in FIDELIO-DKD were excluded from the full analysis set due to substantial Good Clinical Practice violations, resulting in 5,674 patients (99.0%) in whom the primary analysis will be performed.
More than 40% of the patients were recruited in Europe, with a similar number in Western and Eastern Europe, 16.6% in North America, 10.5% in Latin America, 27.8% in Asia, and 3.5% in Australia, New Zealand, and South Africa (region "Other").
The overall trial population is predominately male (70.2%) and white (65.9%), with a mean age of 65. 6 medication. Approximately 2/3 (64.1%) were using insulin, while metformin was the most frequently used glucose-lowering oral drug at baseline. Glucagon-like peptide 1 agonists were used by 7.0% of patients, while 4.5% were using SGLT2 inhibitors.
At baseline, nearly all patients (97.0%) had arterial hypertension as concomitant disease, and 46.8% had diabetic retinopathy. Less than half (45.9%) had CV disease (CVD) in the medical history: 29.8% had coronary artery disease, 13.5% myocardial infarction, 12.1% ischemic stroke, 16.2% peripheral artery disease, and 1.3% had a carotid endarterectomy. Only 7.5% of all patients suffered from heart failure at baseline, which is related to the protocol-requested exclusion of all patients with heart failure with reduced ejection fraction with New York Heart Association class II-IV at run-in and screening. Further information about the baseline characteristics can be found in Table 2 and in online supplementary Table S1 (see www.karger.com/doi/10.1159/000503713).
Discussion
Treatment of CKD in general has evolved over the last few decades, resulting in a slowing of progression of kidney disease from 10 to 12 mL/min/year to approximately 2 mL/min/year in patients with an eGFR < 60 mL/min/1.73 m 2 , normal decline being around 0.7-0.9 mL/min/year [10] . Newer treatments to help glycemic control have also translated into further slowing of CKD progression (eGFR decline of 1.85 mL/min/year) as well as further reduction of CV events in T2D patients [6, 29] . However, despite this promising progress T2D patients with CKD still exhibit residual cardiorenal morbidity and mortality. Since 2001, numerous trials assessing various agents with a variety of mechanisms have failed to slow CKD progression over RAS blockers. Attempts were made to reduce the high CV and renal risk in patients already taking RAS inhibitor monotherapy by adding a second RAS blocker: in the Veterans Affairs Nephropathy in Diabetes trial, an ACEI in combination with an ARB [30] , and in the Aliskiren Trial in T2D using Cardiorenal Endpoints, the combination of an ARB with the renin inhibitor aliskiren were investigated [31] . Dual RAS blockade increased the frequency of serious adverse events such as acute kidney injury, hyperkalemia, or stroke, and therefore cannot be recommended in T2D patients with CKD.
More recently, the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation study investigating canagliflozin in patients with T2D and CKD with very high albuminuria found a 30% risk reduction for progression to ESRD, doubling of serum creatinine, or CV or renal death over placebo in patients already receiving RAS blockers [6] . In a meta-analysis by Zelniker et al. [32] , the effect of SGLT2 inhibitors on major adverse CV events (i.e., myocardial infarction, stroke, or CV death) and renal outcomes was analyzed. SGLT2 inhibitors reduced major adverse CV events by 11%, with benefit seen only in patients with atherosclerotic CVD (14% risk reduction) and not in those without. SGLT2 inhibitors reduced the risk of CV death or hospitalization for heart failure by 23%, with a similar benefit in patients with and without atherosclerotic CVD and with and without a history of heart failure. The magnitude of benefit of SGLT2 inhibitors varied with baseline renal function and showed a lesser reduction in progression of renal disease in patients with more severe kidney disease at baseline.
The use of SGLT2 inhibitors was very low in general when FIDELIO-DKD started recruitment in September 2015. Despite not restricting the use of SGLT2 inhibitors in enrolled patients, it was even lower in the targeted study population, since the initiation of treatment with SGLT2 inhibitors in patients with eGFR < 60 mL/ min/1.73 m 2 was prohibited, and it was recommended to stop treatment with SGLT2 inhibitors in patients with eGFR persistently < 45 mL/min/1.73 m 2 . At baseline, 4.5% of all randomized patients were treated with SGLT2 in-hibitors. During the trial, the use of SGLT2 increased slightly but is still low (< 10% of patients). Most likely the data collected will not be sufficient for a meaningful subgroup analysis. However, in previous trials treatment with an MRA has never been investigated on top of a RAS blocker in this group of non-heart failure patients and hence the results of FIDELIO-DKD will be able to generate hypotheses for further investigations.
Inflammation and fibrosis mediated by MR overactivation are also observed in the kidney [33] . The resulting glomerular podocyte injury and mesangial cell proliferation may manifest as glomerular injury, renal vasoconstriction, and albuminuria. Targeting MR overactivation with MRAs, based on the studies conducted so far, showed a sustained reduction in albuminuria of ≥30%, a biomarker that has now been validated as surrogate for slowing CKD progression [13, 34, 35] . It is therefore reasonable to assume that MR blockade, if safe, may offer additional benefit when added to monotherapy with a RAS blocker by attenuating aldosterone breakthrough, and through inhibition of deleterious effects of aldosterone, such as renal inflammation and fibrosis.
The currently available steroidal MRAs, spironolactone and eplerenone, have been investigated in clinical studies that varied between 4 and 52 weeks in duration and assessed the effects on albuminuria in different CKD populations. However, to date, all studies are plagued with hyperkalemia as a major complication of this class. In a recent meta-analysis, Yang et al. [36] concluded that treatment with spironolactone in patients with moderate to severe (stage 3-4) CKD was associated with a lower risk of ESRD (relative risk 34%) but was complicated by a higher risk of hyperkalemia-associated hospitalization (3 times greater risk). They concluded that the renoprotective benefit of spironolactone may be offset by the hyperkalemia risk. In another clinical study of heart failure patients, Trevisan et al. [37] concluded that in an unselected cohort of new users of MRAs, hyperkalemia was very common and frequently followed by therapy interruption, especially among participants with CKD. As a result, the median time on MRA treatment during the initial 12 months of treatment was 179 days (130-346 days), with 24% of remaining patients on therapy after 12 months. Participants with CKD were at highest risk of hyperkalemia and discontinuation. In an investigation analyzing electronic medical records of a diverse US population, Collins et al. [38] found that serum potassium elevation even above 5 mEq/L was associated with an increase in CV risk. Hyperkalemia requiring dose reduction or even discontinuation of a RAS inhibitor may also have Am J Nephrol 2019;50:333-344 DOI: 10.1159/000503713 a negative impact on the prognosis in T2D patients with CKD or heart failure [38] .
Hyperkalemia is a disabler of renal function-preserving medications. In a post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan study, Miao et al. [39] demonstrated that patients who achieved mean serum potassium ≥5 mEq/L during follow-up had a 43% higher risk of the composite endpoint of doubling of serum creatinine or ESRD after controlling for potential confounders. They concluded that treatment with losartan is associated with a high risk of elevated serum potassium levels in patients with diabetes mellitus and nephropathy. These elevated serum potassium levels are in turn associated with an increased risk of renal progression and offset the renoprotective effects of losartan. Given that the major risk factors for hyperkalemia are eGFR < 45 mL/min/1.73 m 2 or serum potassium > 4.5 mEq/L on diuretics [40] , it is clear that those with CKD in T2D patients will be at highest risk, so we restricted recruitment to patients with potassium levels up to 4.8 mEq/L.
Finerenone is a novel, non-steroidal, selective MRA that is associated with lower rates of hyperkalemia compared to steroidal MRAs [41] . In the Mineralocorticoid-Receptor Antagonist Tolerability Study-Diabetic Nephropathy Study, finerenone induced a dose-dependent reduction of UACR, with the largest placebo-corrected reduction (-38%) in the group being treated with 20 mg once daily. Finerenone dosages over 90 days of treatment resulted in small declines in eGFR (∼2-4 mL/min/1.73 m 2 ) and blood pressure (3-5 mm Hg) as well as small changes in serum potassium (+0.2 mEq/L) [27] .
FIDELIO-DKD is the largest renal study recruited to specifically investigate the progression of kidney disease in T2D patients with CKD. While the primary focus is on renal outcomes, potential benefits on CV events will be assessed as well. Unlike previous outcome trials where the levels of albuminuria and kidney function were advanced into stages 3 and 4, FIDELIO-DKD has also included a cohort of patients with lower levels of albuminuria (high albuminuria defined as UACR ≥30 but < 300 mg/g) and stage 2 CKD (eGFR 60-75 mL/min/1.73 m 2 ). FIDELIO-DKD is part of a larger Phase III program that consists of 2 largescale, event-driven outcome trials, FIDELIO-DKD and FIGARO-DKD, an event-driven trial investigating the cardiorenal effects of finerenone in T2D patients with less advanced kidney disease. Complemented by the results of FIGARO-DKD where even T2D patients with stage 2 CKD with high and very high albuminuria and stage 1 CKD patients with very high albuminuria are included, the pro-gram will allow evaluation of the effects of finerenone in the broadest spectrum of CKD patients with T2D ever investigated. Finerenone was developed neither as an antihypertensive agent nor as a glucose-lowering drug being repurposed for a population with kidney impairment. Instead, it was designed to alleviate disease burden in patients with cardiorenal diseases, especially in T2D patients.
The results of FIDELIO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of progression of their renal disease and CV events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Results are expected in 2020.
